Clinical Trial Update: FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing FOLFOXIRI + Bevacizumab + Atezolizumab versus FOLFOXIRI + Bevacizumab as first-line therapy for unresectable metastatic colorectal cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFOXIRI + Bevacizumab
• FOLFOXIRI + Bevacizumab + Atezolizumab

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED